Table 1 The characteristic of the thoracic ESCC patients (n = 163)
Age, yrs. (median) | 66 (range 34–82) |
|---|---|
Gender, males/females | 135 / 28 |
Location: upper/middle/lower | 25 / 97 / 41 |
Clinical stage: | |
 cT1/cT2/cT3 | 87 / 40 / 36 |
 cN0/cN1/cN2 | 113 / 42 / 8 |
 cM0/cM1(LYM) | 162 / 1 |
 cStage (I/II/III/IV) | 100 / 35 / 27 / 1 |
Pathological stage: | |
 pT1 / pT2 / pT3 / pT4 | 93 / 21 / 47 / 2 |
 pN0 / pN1 / pN2 / pN3 | 88 / 45 / 22 / 8 |
 pM0 / pM1(LYM) | 159 / 4 |
 pStage, I / II / III / IV | 75 / 41 / 37 / 10 |
Postoperative therapy: | |
 Absent/present | 127 / 36 |
 Chemotherapy | 24 |
 Chemotherapy and cancer-specific vaccine therapy | 5 |
 Cancer-specific vaccine therapy | 5 |
 CRT | 2 |
 Median follow-up duration, months (range) | 60.0 (3–72) |
 Recurrence, negative/positive | 112 / 51 |
 Censored patients/death | 104 / 59 |